JP2021529807A5 - - Google Patents
Info
- Publication number
- JP2021529807A5 JP2021529807A5 JP2021500187A JP2021500187A JP2021529807A5 JP 2021529807 A5 JP2021529807 A5 JP 2021529807A5 JP 2021500187 A JP2021500187 A JP 2021500187A JP 2021500187 A JP2021500187 A JP 2021500187A JP 2021529807 A5 JP2021529807 A5 JP 2021529807A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- membered
- alkyl
- choice
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694118P | 2018-07-05 | 2018-07-05 | |
| US62/694,118 | 2018-07-05 | ||
| PCT/US2019/040507 WO2020010204A1 (en) | 2018-07-05 | 2019-07-03 | Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529807A JP2021529807A (ja) | 2021-11-04 |
| JP2021529807A5 true JP2021529807A5 (https=) | 2022-07-11 |
Family
ID=69060000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500187A Pending JP2021529807A (ja) | 2018-07-05 | 2019-07-03 | タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230070613A1 (https=) |
| EP (1) | EP3817745A4 (https=) |
| JP (1) | JP2021529807A (https=) |
| CN (1) | CN112714646A (https=) |
| CA (1) | CA3105121A1 (https=) |
| WO (1) | WO2020010204A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190084063A (ko) | 2016-10-28 | 2019-07-15 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Ｅｚｈ２-매개성 암 치료용 조성물 및 방법 |
| EP3810145A4 (en) | 2018-06-21 | 2022-06-01 | Icahn School of Medicine at Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| JP7503851B2 (ja) | 2019-05-06 | 2024-06-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| CN113354619B (zh) * | 2021-06-24 | 2024-03-19 | 皖南医学院 | 一种靶向泛素化降解酪氨酸酶的化合物及其制备方法和应用 |
| CN113956233B (zh) * | 2021-10-22 | 2023-06-06 | 南方医科大学 | 一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用 |
| CA3242835A1 (en) * | 2022-01-07 | 2023-07-13 | Dana-Farber Cancer Institute, Inc. | Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101316101B1 (ko) * | 2011-05-26 | 2013-10-11 | 연세대학교 산학협력단 | Ｐｔｋ 6의 활성 억제용 조성물 및 이를 이용한 암 예방 및 치료용 조성물 |
| KR102668696B1 (ko) * | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| EP3083602A1 (en) * | 2013-12-20 | 2016-10-26 | Pfizer Limited | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
| RU2738833C9 (ru) * | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CN108137593B (zh) * | 2015-04-21 | 2021-01-05 | 上海交通大学医学院附属瑞金医院 | 蛋白激酶抑制剂的制备和用途 |
| GB201508747D0 (en) * | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| CA2988414C (en) * | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| MX2017016325A (es) * | 2015-06-22 | 2018-03-02 | Ono Pharmaceutical Co | Compuesto inhibidor de cinasa de tumor de mama (brk). |
| WO2017007612A1 (en) * | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017024318A1 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| GB201516243D0 (en) * | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| BR112018008918A8 (pt) * | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| EP3445765A4 (en) * | 2016-04-22 | 2019-09-18 | Dana Farber Cancer Institute, Inc. | DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE |
| CN109790143A (zh) * | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2018106870A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| ES2909234T3 (es) * | 2016-12-21 | 2022-05-05 | Ono Pharmaceutical Co | Compuestos de 6-amino-7,9-dihidro-8H-purin-8-ona como inhibidores de Brk |
-
2019
- 2019-07-03 CA CA3105121A patent/CA3105121A1/en active Pending
- 2019-07-03 WO PCT/US2019/040507 patent/WO2020010204A1/en not_active Ceased
- 2019-07-03 CN CN201980058356.1A patent/CN112714646A/zh active Pending
- 2019-07-03 US US17/256,516 patent/US20230070613A1/en active Pending
- 2019-07-03 JP JP2021500187A patent/JP2021529807A/ja active Pending
- 2019-07-03 EP EP19830269.7A patent/EP3817745A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529807A5 (https=) | ||
| CN114450284B (zh) | 作为bcl-xl蛋白抑制剂的6,7-二氢-5h-吡啶并[2,3-c]哒嗪衍生物 | |
| JP7348906B2 (ja) | フェロトーシス誘導活性を有する化合物およびそれらの使用方法 | |
| CN109311848B (zh) | 可用作shp2抑制剂的新型杂环衍生物 | |
| JP2026067858A (ja) | テトラヒドロ－ピリド［３，４－ｂ］インドールエストロゲン受容体モジュレーター及びその使用 | |
| ES2815098T3 (es) | Conjugados de ligadores (ADCs) con inhibidores de KSP | |
| NL1028927C2 (nl) | Nieuwe verbindingen. | |
| WO2014151030A1 (en) | Cell proliferation inhibitors and conjugates thereof | |
| US20200297725A1 (en) | Allosteric bcr-abl proteolysis targeting chimeric compounds | |
| KR20130133905A (ko) | 트로포미오신-관련 키나제의 억제제인 피롤로[2,3-d]피리미딘 유도체 | |
| JP6782250B2 (ja) | Ｃｔｉファーマコフォアを含有する二官能性細胞毒性剤 | |
| EA017196B1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, конъюгаты, способы получения конъюгатов, фармацевтическая композиция, включающая конъюгат, и их терапевтическое применение | |
| JP7291696B2 (ja) | アルファｖインテグリン阻害剤としてのピロロピラジン誘導体 | |
| WO2017152874A1 (zh) | 一种脲类化合物、其制备方法及其医药用途 | |
| CA3206906A1 (en) | Selective bcl-xl protac compounds and methods of use | |
| CN111601790A (zh) | 作为蛋白激酶抑制剂的杂芳基化合物 | |
| TW202322808A (zh) | 治療疾病之化合物、組合物及方法 | |
| WO2021236695A1 (en) | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | |
| WO2024067818A1 (zh) | 一种用于bcl-2蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 | |
| WO2025051180A1 (zh) | 内酰胺类衍生物及其应用 | |
| JP7080346B2 (ja) | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート | |
| US20250073249A1 (en) | Steroid compound, and preparation method therefor and use thereof | |
| WO2020166592A1 (ja) | ヘミアスタリン誘導体とその抗体薬物複合体 | |
| WO2022017442A1 (zh) | 双功能蛋白降解靶向嵌合体类化合物及其制备方法和医药用途 | |
| WO2021013693A1 (en) | Antibody drug conjugates (adcs) with nampt inhibitors |